Zenas BioPharma (ZBIO) Total Liabilities (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Total Liabilities of $411.9 million for Q1 2026, up 732.88% year-over-year from $49.4 million in Q1 2025, and up 191.07% quarter-over-quarter from $141.5 million in Q4 2025.
Zenas BioPharma (ZBIO) Total Liabilities (2023 - 2026) Analysis & Trends
Zenas BioPharma's Total Liabilities history runs 4 years deep, the most recent figure standing at $411.9 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 732.88% year-over-year to $411.9 million; the TTM figure through Mar 2026 stood at $411.9 million (up 732.88% YoY), while the FY2025 annual figure was $141.5 million, up 146.04% from the prior year.
- Total Liabilities for Q1 2026 stood at $411.9 million, up from $141.5 million in the prior quarter.
- The five-year high for Total Liabilities was $411.9 million in Q1 2026, with the low at $43.8 million in Q4 2023.
- The 4-year median for Total Liabilities is $55.5 million (2024), against an average of $115.9 million.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities surged 31.26% in 2024, then soared 732.88% in 2026.
- Zenas BioPharma's Total Liabilities stood at $43.8 million in 2023, then jumped by 31.26% to $57.5 million in 2024, then soared by 146.04% to $141.5 million in 2025, then jumped by 191.07% to $411.9 million in 2026.
- Business Quant data shows ZBIO's Total Liabilities at $411.9 million in Q1 2026, $141.5 million in Q4 2025, and $125.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | 454.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 454.59 Mn |
| Mar 31, 2026 | 411.85 Mn |
| Dec 31, 2025 | 141.50 Mn |
| Sep 30, 2025 | 125.59 Mn |
| Jun 30, 2025 | 53.46 Mn |
| Mar 31, 2025 | 49.45 Mn |
| Dec 31, 2024 | 57.51 Mn |
| Sep 30, 2024 | 44.00 Mn |
| Dec 31, 2023 | 43.82 Mn |